Back to Search
Start Over
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
- Source :
-
Rheumatology . Jul2024, Vol. 63 Issue 7, p1779-1789. 11p. - Publication Year :
- 2024
-
Abstract
- Objectives To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA). Methods A systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12–24 for b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12–24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank. Results The NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-experienced patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index 90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events. Conclusion Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA. [ABSTRACT FROM AUTHOR]
- Subjects :
- *THERAPEUTIC use of immunoglobulins
*THERAPEUTIC use of monoclonal antibodies
*MEDICAL information storage & retrieval systems
*ANTI-inflammatory agents
*PATIENT safety
*PSORIATIC arthritis
*LEFLUNOMIDE
*METHOTREXATE
*ANTIRHEUMATIC agents
*META-analysis
*DESCRIPTIVE statistics
*SYSTEMATIC reviews
*ODDS ratio
*MEDLINE
*JANUS kinases
*PHOSPHODIESTERASE inhibitors
*DRUG efficacy
*MEDICAL databases
*SULFONAMIDES
*NEUROTRANSMITTER uptake inhibitors
*INTERLEUKINS
*CHEMICAL inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 14620324
- Volume :
- 63
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 178184685
- Full Text :
- https://doi.org/10.1093/rheumatology/kead705